drugset / Trial / NCT04685590
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
Phase 2
Active not recruiting
48 enrolled
Washington University School of Medicine
The University of Texas Health Science Center at San Antonio · collabWake Forest University Health Sciences · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau PET positive
Timeline
- Start
- 2021-12-22
- Primary completion
- 2028-01
- Completion
- 2029-01
Publications
- Gonzales MM, Krishnamurthy S, Garbarino V, Daeihagh AS, Gillispie GJ, Deep G, Craft S, Orr ME. A geroscience motivated approach to treat Alzheimer's disease: Senolytics move to clinical trials. Mech Ageing Dev. 2021 Dec;200:111589. doi: 10.1016/j.mad.2021.111589. Epub 2021 Oct 21.
- Guerrero A, De Strooper B, Arancibia-Carcamo IL. Cellular senescence at the crossroads of inflammation and Alzheimer's disease. Trends Neurosci. 2021 Sep;44(9):714-727. doi: 10.1016/j.tins.2021.06.007. Epub 2021 Aug 5.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Quercetin | Small molecule | 1000 mg | Oral |
| Subject | dasatinib anhydrous | Small molecule | 100 mg | Oral |